Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2409-2421

  Egbertson, Melissa S ^a   Cook, Jacquelynn J ^a   Bednar, Bohumil ^a   Prugh, John D ^a   Bednar, Rodney A ^a   Gaul, Stanley L ^a   Gould, Robert J ^a   Hartman, George D ^a   Homnick, Carl F ^a   Holahan, Marie A ^a   Libby, Laura A ^a   Lynch Jr , Joseph J ^a   Lynch, Robert J ^a   Sitko, Gary R ^a   Stranieri, Maria T ^a   Vassallo, Laura M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; BLEEDING TIME; BLOOD PLATELETS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RADIOLIGAND ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIOPHENES;

EID: 0033168403     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980722p     Document Type: Article

References (39)

1. (a) Philips, D. R.; Charo, I. F.; Parise, L. V. Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. Blood 1988, 71, 831-843.;
2. (b) Philips, D. R.; Kieffer, N. Platelet Membrane Glycoproteins: Function in Cellular Interactions. In Annual Reviews in Cell Biology; Palade, G. E., Ed.; Annual Reviews Inc.: Palo Alto, 1990; Vol. 6, pp 329-357.
3. (a) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Platelet Glycoprotein IIb/IIIa Antagonists. Drugs Future 1994, 19, 135-159.
4. (b) Raddatz, R.; Gante, J. Recent Developments in Glycoprotein IIb/IIIa Antagonists. Expert Opin. Ther. Pat. 1995, 5 (11), 1165-1183.
5. Mckean, M.-L.; Adehnan, S. J. Future Therapies for the Prevention and Treatment of Venous and Arterial Thrombosis. Expert Opin. Invest. Drugs 1998, 7 (5), 687-690.
6. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
7. (a)Egbertson, M. S.; Chang, C. T. C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J., Jr.; Lynch, R. J.; Manno, P. M.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
8. (b) McClellan, K. J.; Goa, K. L. Tirofiban. A Review of its Use in Acute Coronary Snyndromes. Drugs 1998, 56 (6), 1067-1080.
9. Egbertson, M. S.; Naylor, A. M.; Hartman, G. D.; Cook, J. J.; Gould, R. J.; Holahan, M. A.; Lynch, J. J., Jr.; Lynch, R. J.; Stranieri, M. T.; Vassallo, L. M. Non-Peptide Fibrinogen Receptor Antagonists. 3. Design and Discovery of a Centrally Constrained Inhibitor. Bioorg. Med. Chem. Lett. 1994, 4, 1835-1840.
10. We are not alone in employing this strategy; several groups have demonstrated the success of this approach: (a) Alig, L.; Edenhoger, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trzeciak, A.; Weller, T. Low Molecular Weight, Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1992, 35, 4393-4407.
11. 7 Mimetic for the Predicted γ-turn Conformation Found in Several Constrained RGD Antagonists. J. Med. Chem. 1992, 35, 3970-3972.
12. (c) Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burges, J. L.; Callahan, J. F.; Calco, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. S.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide. J. Am. Chem. Soc. 1993, 115, 8861-8862.
13. (d) McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarg, K. D.; Sommers, T. C.; Thorsett, E. D.; Tischler, M.; Webb, R. R.; Venuti, M. C. From Peptide to Non-Peptide. The De Novo Design of Potent, Non-Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold. J. Am. Chem. Soc. 1994, 116, 5077.
14. (e) Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Erhard, K. F.; Keenan, R. M.; Nichols, A.; Peishoff, C. E.; Samenen, J. M.; Wong, A. S.; Huffman, W. F.; Potent Non-Peptide Fibrinogen Receptor Antagonists Which Present an Alternate Pharmacophore. J. Med. Chem. 1995, 38, 9-12.
15. (f) Stilz, H. U.; Jablonka, B.; Just, M.; Knolle, J.; Paulus, E. F.; Zoller, G. Discovery of an Orally Active Non-Peptide Fibrinogen Receptor Antagonist. J. Med. Chem. 1995, 39, 2118-2122.
16. (g) Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. J. Med. Chem. 1995, 38, 3332-3341.
17. (h) Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadváry, P.; Müller, H. M.; Knopp, D.; Levet-Traift, B.; Lipari, M. T.; Modi, N. B.; Müller, M.; Refino, C. J.; Schmitt, M.; Schönholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of amidines. J. Med. Chem. 1996, 39, 3139-3147.
18. (i) Xue, C.-B.; Raafalski, M.; Roderick, J.; Eyermann, C. J.; Mousa, S.; Olsen, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of a Series of Benzimidazole/Benzoxazole Glycoprotein IIb/IIIa Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 339-344.
19. (j) Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1997, 40, 1779-1788.
20. Egbertson, M. S.; Hartman, G. D.; Gould, R. J.; Bednar, B.; Bednar, R. A.; Cook, J. J.; Gaul, L. S.; Holahan, M. A.; Libby, L. A.; Lynch, J. J., Jr.; Lynch, R. J.; Sitko, G. R.; Stranieri, M. T.; Vassallo, L. M. Non-Peptide GPIIb/IIIa inhibitors. 10. Centrally Constrained Alpha-Sulfonamides are Potent Inhibitors of Platelet Aggregation. Bioorg. Med. Chem. Lett. 1996, 6, 2519-2524.
21. Egbertson, M. S.; Bednar, B.; Bednar, R. A.; Hartman, G. D.; Gould, R. J.; Lynch, R. J.; Vassallo, L. M.; Young, S. D. Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 9. Centrally Constrained Alpha-Sulfonamides are Useful Tools for Exploring Platelet Receptor Function. Bioorg. Med. Chem. Lett. 1996, 6 (12), 1415-1420.
22. A portion of this work was first published in Prugh, J. D.; Gould, R. J.; Lynch, H. J.; Zhang, G.; Cook, J. J.; Holahan, M. A.; Stranieri, M. T.; Sitko, G. R.; Gaul, S L.; Bednar, R. A.; Bednar, B.; Hartman, G. D. Nonpeptide GPIIB/IIIA Inhibitors. 16. Thieno[2,3-b]thiophene α-sulfonamides are Potent Inhibitors of Platelet Aggregation. Bioorg. Med. Chem. Lett. 1997, 7, 865-870.
23. Prugh, J. D.; Hartman, G. D.; Mallorga, P. J.; McKeever, B M.; Michelson, S. R.; Murko, M. A.; Schwam, H.; Smith, R. L.; Sondey, J. M.; Springer, J. P.; Sugrue, M. F. New Isomeric Classes of Topically Active Ocular Hypotensive Carbonic Anhydrase Inhibitors: 5-Substituted Thieno[2,3-b]thiophene-2-sulfonamides and 5-Substituted Thieno[3,2-b]thiophen-2-sulfonamides. J. Med. Chem. 1991, 34, 1805-1818.
24. Naylor, A. M.; Egbertson, M. S.; Vassallo, L. M.; Birchenough, L. A.; Zhang, G. X.; Gould, R. J.; Hartman, G. D. Non-Peptide Fibrinogen Receptor Antagonists. 4. Proposed Three-Dimensional Requirements in Centrally Constrained Inhibitors. Bioorg. Med. Chem. Lett. 1994, 4, 1841-1846.
25. Cheresh, D. A. Human Endothelial Cells Synthesize and Express an Arg-Gly-Asp-Directed Adhesion Receptor Involved in Attachment to Fibrinogen and Von Willebrand Factor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6471-6475. Albeida, S. M.; Daise, M.; Levine, E. M.; Buck, C. A. Identification and Characterization of Cell-Stratum Adhesion Receptors on Cultured Human Endothelial Cells. J. Clin. Invest. 1989, 83, 1992-1998. See also ref 4.
26. Cheresh, D. A. Human Endothelial Cells Synthesize and Express an Arg-Gly-Asp-Directed Adhesion Receptor Involved in Attachment to Fibrinogen and Von Willebrand Factor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6471-6475. Albeida, S. M.; Daise, M.; Levine, E. M.; Buck, C. A. Identification and Characterization of Cell-Stratum Adhesion Receptors on Cultured Human Endothelial Cells. J. Clin. Invest. 1989, 83, 1992-1998. See also ref 4.
27. Hutchinson, J. H.; Cook, J. J.; Brashear, K. M.; Breslin, M. J.; Glass, J. D.; Gould, R. J.; Halczenko, W.; Holahan, M. A.; Lynch, R. J.; Sitko, G. R.; Stranieri, M. T.; Hartman, G. D. Non-Peptide Glycoprotein IIb/IIIa Antagonists. 11. Design and in Vivo Evaluation of 3,4-Dihydro-1(1H)-isoquinolinone-Based Antagonists and Ether Ester Prodrugs. J. Med. Chem. 1996, 39, 4583-4591.
28. Gartner, T. K.; Bennett, J. S.; Ogilvie, M. L. Effects of Ala (A) for Gly (G) Substitutions in the (GD) Regions of the Peptides R(GD)S and LGGAKQA(GD)V. Blood 1987, Suppl. 1, 351a.
29. 8 platelets/mL, 20 000 to 1000 000 receptors/platelet).
30. Bednar, R. A.; Gaul, S. L.; Hamill, T. G.; Egbertson, M. S.; Shafer, J. A.; Hartman, G. D.; Gould, R. J.; Bednar, B. Indentification of Low-Molecular Weight GPIIb/IIIa Antagonists that Bind Preferentially to Activated Platelets. J. Pharmacol. Exp. Ther. 1998, 285, 1317-1326.
31. Bednar, B.; Cunningham, M. E.; McQueney, P. A.; Egbertson, M. S.; Askew, B. C.; Bednar, R. A.; Hartman, G. D.; Gould, R. J. Flow Cytometric Measurement of Kinetic and Equilibrium Binding Parameters of RGD Ligands in Binding to GPIIb/IIIa on Platelets. Cytometry 1997, 28, 58-65.
32. For other reports on the affinity of GPIIb/IIIa ligands for resting or activated platelets, see: (a) Kouns, W. C.; Hadvary, P.; Haering, P.; Steiner, B. Conformational Modulation of Purified Glycoprotein GPIIb-IIIa Allows Proteolytic Generation of Active Fragments from Either Active or Inactive GP IIb-IIIa. J. Biol Chem. 1992, 267, 18844-18851.
33. (b) Kunicki, T. J.; Annis, D. S.; Deng, Y. J.; Loftus, J. C.; Shattil, S. J. J. Biol Chem. 1996, 271, 20315-20321.
34. Although the affinity of the compounds for resting platelets is decreased relative to activated receptor, the affinity remains in the low-nanomolar range, and one would expect both activated and unactivated receptors to be fully occupied at the concentrations used for efficacy.
35. Beer, J. H.; Springer, K. T.; Coller, B. S. Immobilized Arg-Gly-Asp(RGD) Peptides of Varying Lengths as Structural Probes of the Platelet Glycoprotein IIb/IIIa. Blood 1992, 79, 117-128.
36. Cook, J. J.; Sitko, G. R.; Holahan, M. A.; Stranieri, M. T.; Glass, J. D.; Askew, B. C.; McIntyre, C. J.; Claremon, D. A.; Baldwin, J. J.; Hartman, G. D.; Gould, R. J.; Lynch, J. J., Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic Efficacy of L-738,167, a Long-Acting GPIIb/IIIa Antagonist, Correlates with Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation but not with Bleeding Time Prolongation. J. Pharmacol. Exp. Ther. 1997, 281, 677-689.
37. Breslow, D. S.; Sloan, M. F.; Newburg, N. R.; Penlow, W. B. Thermal Reactions of Sulfonyl Azides. J. Am. Chem. Soc. 1969, 91, 2273-2279.
38. 2-protected L-2,3-diaminopropanoic Acid. Synthesis 1981, 266-288.
39. Kouns, W. C.; Hadvary, P.; Haering, P.; Steiner, B. Conformational Modulation of Purified Glycoprotein GPIIb-IIIa Allows Proteolytic Generation of Active Fragments from Either Active or Inactive GP IIb-IIIa. J. Biol Chem. 1992, 267, 18844-18851.